Phase 1Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Sponsored by NextCure, Inc.
About this study
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Enrolling at this location
Roswell Park Comprehensive Cancer Center
Buffalo, New York
I'm interestedThis study also enrolls at 13 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.